![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Amgen Snatches Up Medigene Cancer Spin-Off
Amgen Snatches Up Medigene Cancer Spin-Off
![Amgen](https://www.fdanews.com/ext/resources/test/Drug-Images4/Amgen_logo.jpg?t=1614976958&width=430)
A week after unveiling key management changes — including a new CEO — Medigene said Amgen was acquiring its U.S. spin-off, Catherex.
The agreement includes an upfront payment of $10.5 million from Amgen. In addition, Medigene — which is based in Martinsried, Germany — will be entitled to payments upon the achievement of certain regulatory and sales-based milestones for Imlygic. The FDA approved it for the treatment of advanced metastatic melanoma in October.
Catherex owns a patent portfolio in the field of oncolytic viruses, which Amgen now will own.
Upcoming Events
-
21Oct